Strategic Contract2026-05-06
Aimed Bio Inc. R&D Expenses
에임드
에임드바이오
0009K0
Signal Score
64B — Moderate Signal
Score64 / 100
Historical Avg Return (5d)
+2.00%
Data Coverage
100%n=537
Risk-adjusted indicator based on 537 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Research and Development Expenses: Over 10% of 2025 Operating Revenue (approximately 47.3B KRW)
- • Contract Date: 2025-10-15
3 more figures — unlock with API access
AI Analysis Summary
Developer & Pro plans
Risk Factors
Developer & Pro plans
Access Full Korean Market Signal Analytics
✔ AI-parsed DART filing classification & scoring
✔ Real-time event impact indicators
✔ Historical pattern data via REST API
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.
AI-processed analysis. Based on: 투자판단관련주요경영사항 (ODS025 기술이전계약 관련 연구개발비 수령). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.